Publication:
The first effect of COVID-19 pandemic on starting biological disease modifying anti-rheumatic drugs: Outcomes from the treasure real-life database

Thumbnail Image

Organizational Units

Authors

Kanitez, Nilüfer Alpay
Kiraz, Sedat
Dalkılıç, Ediz
Kimyon, Gezmiş
Mercan, Rıdvan
Karadağ, Ömer
Beş, Cemal
Kılış, Levent
Akar, Servet
Ateş, Aşkın

Advisor

Language

Publisher:

Aves

Journal Title

Journal ISSN

Volume Title

Abstract

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic.

Description

Source:

Keywords:

Keywords

Society classification criteria, Bath ankylosing-spondylitis, Spondyloarthritis, Reliability, Biological disease-modifying anti-rheumatic drug, Coronavirus disease 2019, Rheumatoid arthritis, Spondyloarthritis, Science & technology, Life sciences & biomedicine, Rheumatology

Citation

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details